Intelligent Bio Solutions Inc. reported strong revenue growth driven by significant increases in reader and cartridge sales, indicating successful execution of their razor-razorblade model. The company is strategically investing in commercial expansion and regulatory pathways, particularly for U.S. market entry, while maintaining financial discipline.
Total revenue for the fiscal second quarter increased 48% year-over-year to $896,774.
positiveReader sales surged 104% year-over-year to $246,519, expanding the installed base.
positiveCartridge sales grew 33% year-over-year to $516,754, demonstrating recurring revenue momentum.
positiveGross profit margins for the first half of fiscal 2026 increased to 49%, up 10% year-over-year.
positiveClosed a $10.0 million private placement, receiving net proceeds of $9.40 million to strengthen the balance sheet.
positiveOperating expenses increased significantly year-over-year, with Selling, general and administrative expenses up from $1.81M to $2.34M for the quarter.
attentionNet loss attributable to Intelligent Bio Solutions Inc. for the quarter was $2.68 million, compared to $2.25 million in the prior year period.
negativeDevelopment and regulatory approval expenses increased year-over-year for the six-month period, from $1.46M to $1.01M, though this is a decrease from the prior year's six-month period.
attentionImpairment of long-lived assets of $27,147 for the quarter and $288,927 for the six-month period.
negativeMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Reader Sales | N/A | — | — | — |
Cartridge Sales | N/A | — | — | — |
Other Sales | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Reader sales more than doubling shows market demand for our non-invasive fingerprint drug testing technology and significantly expands our installed base, the engine for future recurring revenue.
Equally important is the 33% growth in cartridge sales, which confirms existing customers are actively using our system and reordering consumables. This is our razor-razorblade model working as designed - hardware placements create the foundation, and consumable sales deliver ongoing revenue.
With strong year-over-year growth and first-half revenue exceeding $2 million, we’re building sustainable momentum as we advance our regulatory pathway toward planned U.S. market entry.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.